Trial reportAtherosclerosis2013
Hypercholesterolemia and reduced HDL-C promote hematopoietic stem cell proliferation and monocytosis: studies in mice and FH children.
Trial report in Atherosclerosis, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 114 citations in OpenAlex.
- Bone marrow activation in response to metabolic syndrome and early atherosclerosis.European heart journal · 2022Trial
- Prime time for the use of statins in MPNs: from comorbidity drugs to disease-modifying partners.Blood advances · 2026Review
- CD80Cell communication and signaling : CCS · 2026Article
- Trained immunity: new paradigm in the immunological memory of cardiovascular disease.ImmunoHorizons · 2026Review
- Hepatic steatosis associates with leukopoietic activity and atherosclerotic inflammation: mechanistic insights into cardiovascular risk.Metabolism: clinical and experimental · 2026Article
- Cyp7b1-inhibiting azoles as novel enhancers of hematopoietic stem and progenitor cell mobilization.bioRxiv : the preprint server for biology · 2025Article
- Clonal hematopoiesis of indeterminate potential: contribution to disease and promising interventions.Molecular and cellular biochemistry · 2025Review
- Association of neutrophil to high density lipoprotein cholesterol ratio with aortic dissection and aneurysm risk: epidemiological insights from prospective cohort study based on UK biobank.BMC public health · 2025Article
- Serum Lipids, Inflammation, and the Risk of Atrial Fibrillation: Pathophysiological Links and Clinical Evidence.Journal of clinical medicine · 2025Review
- Bone Marrow Niche in Cardiometabolic Disease: Mechanisms and Therapeutic Potential.Circulation research · 2025Review
- Atypical monocyte dynamics in healthy humans in response to fasting and refeeding are distinguished by fasting HDL and postprandial cortisol.American journal of physiology. Endocrinology and metabolism · 2024Article
- Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2024Review
- Macrophage profiling in atherosclerosis: understanding the unstable plaque.Basic research in cardiology · 2024Review
- Trehalose promotes atherosclerosis regression in female mice.Frontiers in cardiovascular medicine · 2024Article
- The Relationship of Cholesterol Responses to Mitochondrial Dysfunction and Lung Inflammation in Chronic Obstructive Pulmonary Disease.Medicina (Kaunas, Lithuania) · 2023Review
- Tuning macrophages for atherosclerosis treatment.Regenerative biomaterials · 2023Review
- Innate and Acquired Cellular Immunity in Children with Familial Hypercholesterolemia Treated with Simvastatin.Journal of clinical medicine · 2022Article
- Systemic consequences of abnormal cholesterol handling: Interdependent pathways of inflammation and dyslipidemia.Frontiers in immunology · 2022Review
- The Novel Predictive Biomarkers for Type 2 Diabetes Mellitus in Active Pulmonary Tuberculosis Patients.Infection and drug resistance · 2022Article
- The iterative lipid impact on inflammation in atherosclerosis.Current opinion in lipidology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
Previous studies have shown that mice with defects in cellular cholesterol efflux show hematopoietic stem cell (HSPC) and myeloid proliferation, contributing to atherogenesis. We hypothesized that the combination of hypercholesterolemia and defective cholesterol efflux would promote HSPC expansion and leukocytosis more prominently than either alone. We crossed Ldlr(-/-) with Apoa1(-/-) mice and found that compared to Ldlr(-/-) mice, Ldlr(-/-)/Apoa1(+/-) mice, with similar LDL-cholesterol levels but reduced HDL-cholesterol (HDL-C) levels, had expansion of HSPCs, monocytosis and neutrophilia. Ex vivo studies showed that HSPCs expressed high levels of Ldlr, Scarb1 (Srb1), and Lrp1 and were able to take up both native and oxidized LDL. Native LDL directly stimulated HSPC proliferation, while co-incubation with reconstituted HDL attenuated this effect. We also assessed the impact of HDL-C levels on monocytes in children with familial hypercholesterolemia (FH) (n = 49) and found that subjects with the lowest level of HDL-C, had increased monocyte counts compared to the mid and higher HDL-C levels. Overall, HDL-C was inversely correlated with the monocyte count. These data suggest that in mice, a balance of cholesterol uptake and efflux mechanisms may be one factor in driving HSPC proliferation and monocytosis. Higher monocyte counts in children with FH and low HDL-cholesterol suggest a similar pattern in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.